adeno-associated virus mediated midi-dystrophin gene replacement therapy (Kinea Bio)

N/A

Report date: 2025/06/11 10:45:31

Base Information

Drug Nameadeno-associated virus mediated midi-dystrophin gene replacement therapy (Kinea Bio)
Drug Alias Namedystrophin gene therapy (Kinea Bio)KN-123
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionDystrophin modulators
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKinea Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesKinea Bio Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A